Aclaris Therapeutics, Inc. (ACRS) Starts Phase 2b Trial in Lichen Planus
Aclaris Therapeutics (ACRS) began a Phase 2b trial of modzatinib for lichen planus, enrolling 100 participants. The FDA granted Fast Track designation. The trial is randomized and placebo-controlled, focusing on oral erosive lichen planus first.
How this was made

The 30-second read
Why it matters
Aclaris gains a regulatory milestone and a potential market differentiator in lichen planus treatment.
Market read
First‑report trial start provides a fresh catalyst for ACRS and may influence peer valuations.
What to watch
Fast Track designation may accelerate regulatory review, but enrollment risk remains.
Background
Phase 2b trials test efficacy and safety in a larger patient group after Phase 1 establishes dosing.
Ticker impact
Aclaris Therapeutics announced the start of a Phase 2b trial for modzatinib in lichen planus, a first‑report clinical development update.
potential upside as investors price in future efficacy data
Phase 2b starts are material for biotech valuations; no data yet, but market typically reacts positively to trial progress.
Market effects
May boost sentiment for dermatology and rare‑disease biotech peers.
Limited to US biotech sector.
Low global impact beyond niche therapeutic area.
Counterpoint
If the trial fails to meet endpoints, the stock could face sharp downside.
Key entities
- companyAclaris Therapeutics, Inc.
Biopharma developing modzatinib for dermatologic conditions.

